Answers are grounded in this paper and cite their sources.
Uveal melanoma (UM) patients frequently develop advanced-stage disease in the liver, but treatment options are limited. The low tumor mutation burden and the transcriptional rewiring observed in aggressive, BRCA1-associated protein 1 (BAP1)-deficient UM led us to investigate transcriptional-based inhibitors in preclinical models. Drug screening data and analysis of the Dependency Map (DepMap) indicated that UM cell lines exhibit a strong dependency on the transcriptional cyclin-dependent kinases, 7 and 9 (CDK7/9). Treatment of BAP1-deficient UM cell lines with SY-5609, a CDK7 inhibitor, led to growth inhibition associated with stalled cell cycle progression. Casein kinase 1 alpha (CK1α) is highly expressed in BAP1-deficient UM patient tumors and treatment of BAP1-deficient UM cell lines with A51, a CDK7/9 plus CK1α inhibitor led to both cell cycle arrest and induction of cell death. RNA-sequencing and protein array analysis associated A51 effects with down-regulation of the pro-survival protein, MCL1. Depletion of MCL1 enhanced cell death in SY-5609-treated UM cells, whereas overexpression of MCL1 rescued cell death in A51-treated UM cells. In a non-invasive in vivo liver injection model of UM tumor growth, A51 reduced tumor onset and improved overall survival. Overall, these studies show that A51 causes cell death in advanced-stage UM preclinical models, at least in part, through down-regulating MCL1.
No takes yet. Share an insight, caveat, or question.
Waltrich et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: